Exome sequencing of tumors from the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development
Egle, A; Gassner, FJ; Hopner, JP; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Zaborsky, N ONCOL RES TREAT. 2018; 41: 31-31.
Spatial heterogeneity in diffuse large B-cell lymphoma
Magnes, T; Melchardt, T; Thorner, A; Neureiter, D; Klieser, E; Greil, R; Egle, A ONCOL RES TREAT. 2018; 41: 243-244.
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group
Fuchs, M; Goergen, H; Kobe, C; Eich, H; Baues, C; Greil, R; Sasse, S; Zijlstra, JM; Lohri, A; Rosenwald, A; von Tresckow, B; Diehl, V; Kuhnert, G; Dietlein, M; Borchmann, P; Engert, A BLOOD. 2018; 132:
Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study
Greil, R; Fraser, G; Leber, B; Marks, R; Quaresmini, G; Middeke, JM; Semenzato, G; Schary, W; Boyer, M; Breuleux, M; Crompton, N; Humphrey, K; Marlton, P BLOOD. 2018; 132:
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Burtness, B; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; De Castro, G; Psyrri, A; Rotllan, NB; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Roy, A; Cheng, J; Jin, F; Rischin, D ANN ONCOL. 2018; 29:
Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Samoilova, O; Novak, J; Ben-Yehuda, D; Strugov, V; Gill, D; Gribben, JG; Hsu, E; Zhou, C; Clow, F; James, DF; Styles, L; Flinn, IW BLOOD. 2018; 132:
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera – Final Phase I/II Peginvera Study Results
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Forjan, E; Willenbacher, E; Wolf, D; Kralovics, R; Gisslinger, B; Stampfl-Mattersberger, M; Egle, A; Melchardt, T; Burgstaller, S; Schalling, M; Krauth, MT; Greil, R; Kadlecova, P; Zoerer, M; Empson, V; Grohmann-Izay, B; Klade, C BLOOD. 2018; 132:
mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort
Filipits, M; Rudas, M; Singer, C; Bago-Horvath, Z; Greil, R; Balic, M; Lax, SF; Wu, N; Zhao, S; Weidler, J; Bates, M; Hlauschek, D; Gnant, M; Dubsky, P ANN ONCOL. 2018; 29: 480-480.
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study
Schlenk, RF; Paschka, P; Krzykalla, J; Weber, D; Kapp-Schwoerer, S; Gaidzik, VI; Leis, C; Fiedler, W; Kindler, T; Schroeder, T; Mayer, K; Lubbert, M; Wattad, MA; Gotze, KS; Horst, HA; Koller, E; Wulf, G; Schleicher, J; Bentz, M; Greil, R; Hertenstein, B; Krauter, J; Martens, U; Nachbaur, D; Abu Samra, M; Girschikofsky, M; Benner, A; Thol, F; Heuser, M; Ganser, A; Dohner, K BLOOD. 2018; 132:
Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiveing First-Line Immuno-Chemotherapy in 2 Prospective StiL Trails – the Effects of Riruximab Maintenance
Kobbe, G; Pechtel, S; Zohren, F; Barth, J; Burchardt, AC; Buske, C; Dienst, A; Germing, U; Greil, R; Hertenstein, B; Kauff, F; Koenigsmann, M; Lerchenmuller, C; Schroeder, TM; Haas, R; Rummel, MJ BLOOD. 2018; 132:
